Palatin Announces FDA Review of IND Application for Combined Administration of Bremelanotide and Tirzepatide (GLP-1) for the Treatment of Obesity.
Phase 2 doctoral studies expected to begin in mid-calendar 2024 Running the KOL event “Beyond GLPs” at May 8, 2024
Read More